The company's pipeline includes alfimeprase for the treatment of thrombotic-related disorders, NU172 for use as a short-acting anticoagulant during medical or surgical procedures, and NU206 for the treatment of chemotherapy/radiation therapy-induced mucositis and inflammatory bowel disease. Additionally, Nuvelo has research programs in leukemia therapeutic antibodies and Wnt signaling pathway therapeutics to expand its pipeline and create more partnering and licensing opportunities. Nuvelo's mission is to develop and commercialize therapeutics that improve life.